Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

Table 5

Changes in residual urine volume and QT interval in the long-term analysis set.

Variable		Imidafenacin	Solifenacin
Number of subjects		11	14
Residual urine volume (mL)
0 week	(Mean ± SD)	15.1±14.7	13.4±11.0
4 week	(Mean ± SD)	30.9±20.4^∗	38.6±32.1^∗∗	NS
12 week	(Mean ± SD)	30.7±28.0	30.6±27.7^∗	NS
52 week	(Mean ± SD)	20.6±25.4	31.1±23.4^∗∗	NS
QT interval (ms)
0 week	(Mean ± SD)	413.6±24.6	426.9±22.4
4 week	(Mean ± SD)	415.8±18.9	426.2±20.1	NS
12 week	(Mean ± SD)	416.4±18.4	427.2±23.0	NS
52 week	(Mean ± SD)	417.0±20.3	424.4±22.5	NS

Intragroup (versus 0 weeks: the end of the observation period)
Paired t-test *: 𝑃<0.05, **: 𝑃<0.01
Intergroup: Unpaired t-test, NS: not significant, SD: standard deviation.